Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Reference Data and Predictors of HR-pQCT-Derived Muscle Density and Its Prediction of Physical Performance.

There is increasing awareness of a role for muscle composition in sarcopenia and cachexia. Computed tomography (CT)-based measures of muscle density (MusD) are commonly used to indicate composition, with a decrease in MusD reflecting an increase in muscle fat infiltration....

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreReference Data and Predictors of HR-pQCT-Derived Muscle Density and Its Prediction of Physical Performance.

Unravelling the Role of PIEZO1 in Adipogenesis of Fibrogenic/Adipogenic Progenitors for Muscle Fat Infiltration After Rotator Cuff Tear.

Muscular fatty infiltration originated from fibrogenic/adipogenic progenitors (FAPs) is a common issue following rotator cuff tear (RCT) that impairs shoulder function. RCT disrupted the biomechanical equilibrium of the shoulder and decreased the mechanical stimuli transmitted to the rotator cuff. Whether...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreUnravelling the Role of PIEZO1 in Adipogenesis of Fibrogenic/Adipogenic Progenitors for Muscle Fat Infiltration After Rotator Cuff Tear.

Circulating miR-144-3p as a Novel Independent Biomarker Associated With Low Muscle Strength Among Older Adults.

Low muscle strength, a key component of sarcopenia, is significant in the development of adverse health outcomes among older adults. MicroRNAs (miRNAs) have been implicated in mechanisms of sarcopenia; however, their specific functions in sarcopenia components, particularly low muscle strength,...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCirculating miR-144-3p as a Novel Independent Biomarker Associated With Low Muscle Strength Among Older Adults.

Dual Roles of HbA1c Variability and Body Composition for Cardiovascular Risk: A Cohort Study of 8224 Adults With Type 2 Diabetes Mellitus.

Glycaemic variability and body composition are emerging predictors of cardiovascular disease (CVD) in patients with Type 2 diabetes mellitus (T2DM); however, their combined impact remains unclear. We investigated the association among HbA1c variability, body composition parameters and cardiovascular outcomes in...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDual Roles of HbA1c Variability and Body Composition for Cardiovascular Risk: A Cohort Study of 8224 Adults With Type 2 Diabetes Mellitus.

ODIASP: An Open-Source Software for Automated SMI Determination-Application to an Inpatient Population.

The diagnosis of malnutrition has evolved with the GLIM recommendations, which advocate for integrating phenotypic criteria, including muscle mass measurement. The GLIM framework specifically suggests using skeletal muscle index (SMI) assessed via CT scan at the third lumbar level (L3)...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreODIASP: An Open-Source Software for Automated SMI Determination-Application to an Inpatient Population.

Recent Sarcopenia Definitions-Variability in Prevalence and Disability Associations in Peritoneal Dialysis Patients.

Sarcopenia is common in chronic kidney disease, but no unified consensus exists regarding its diagnostic criteria. New definitions, including the Sarcopenia Definitions and Outcomes Consortium (SDOC), define sarcopenia based on decreased muscle function without measuring muscle mass. However, the application...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRecent Sarcopenia Definitions-Variability in Prevalence and Disability Associations in Peritoneal Dialysis Patients.

B0092 tumor-bearing mice are a new model for the study of cachexia in head and neck cancer.

Introduction: Head and neck cancer (HNC) accounts for ~4% of all cancers but causes ~15,000 deaths annually in the U.S. Over 40% of HNC patients present with cachexia, a severe comorbidity associated with skeletal muscle defects, worsened treatment response, and...

๐Ÿ—“๏ธ 2025-07-21
๐Ÿ“ฐ Publication: American Journal Of Physiology-Cell Physiology
Read MoreB0092 tumor-bearing mice are a new model for the study of cachexia in head and neck cancer.

Impact of sarcopenia and changes in skeletal muscle mass on prognosis of patients with pancreatic ductal adenocarcinoma receiving chemotherapy with first-line gemcitabine and nab-paclitaxel: a prospective study.

Sarcopenia is an important prognostic factor for cancer patients. Here, we prospectively examined the effects of sarcopenia on progression-free survival (PFS) and overall survival (OS) of patients with pancreatic ductal adenocarcinoma (PDAC) treated with first-line gemcitabine and nab-paclitaxel (GnP). This...

๐Ÿ—“๏ธ 2025-07-17
๐Ÿ“ฐ Publication: Journal Of Gastroenterology
Read MoreImpact of sarcopenia and changes in skeletal muscle mass on prognosis of patients with pancreatic ductal adenocarcinoma receiving chemotherapy with first-line gemcitabine and nab-paclitaxel: a prospective study.

Oral apigenin prevents obesity-related muscular atrophy, but not obesity itself, in middle-aged rats fed a high-calorie diet.

Obesity constitutes a growing global health concern, affecting individuals during the aging process. Flavonoids that increase tissue NAD+โ€ฏlevels, such as apigenin (Api), are proposed for the treatment of obesity and age-related diseases. Thus, this study aimed to provide initial preclinical...

๐Ÿ—“๏ธ 2025-07-12
๐Ÿ“ฐ Publication: Biomedicine & Pharmacotherapy
Read MoreOral apigenin prevents obesity-related muscular atrophy, but not obesity itself, in middle-aged rats fed a high-calorie diet.

TAVI Success Is More Than Just the Valve: CT-Derived Sarcopenia as a Major Determinant of Long-Term Survival.

Sarcopenia, characterized by progressive skeletal muscle loss, is a silent yet powerful marker associated with survival, yet its impact on long-term outcomes in transcatheter aortic valve implantation (TAVI) remains underestimated. While frailty has been recognized as a main factor of...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTAVI Success Is More Than Just the Valve: CT-Derived Sarcopenia as a Major Determinant of Long-Term Survival.

Skeletal Muscle-Specific Deletion of E3 Ligase Asb2 Enhances Muscle Mass and Strength.

Maintaining skeletal muscle mass and strength is crucial to prevent sarcopenia during healthy ageing. Ankyrin repeat and suppressor of cytokine signalling box protein 2 (Asb2), an E3 ligase, has been implicated in regulating muscle mass; however, its roles on muscle...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSkeletal Muscle-Specific Deletion of E3 Ligase Asb2 Enhances Muscle Mass and Strength.

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 โ€“ Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 โ€“ The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP.ย Why cachexia kills: examining the causality of poor outcomes in wasting conditions.ย J Cachexia Sarcopenia Muscle 2013; 4: 89โ€“94.

Evans WJ, Morley JE, Argilรฉs J, Bales C, Baracos V, Guttridge D, et al.ย Cachexia: a new definition.ย Clin Nutr 2008; 27: 793โ€“799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al.ย Muscle wasting disease: a proposal for a new disease classification.ย J Cachexia Sarcopenia Muscle 2014; 5: 1โ€“3.

Argiles JM, Busquets S, Stemmler B, Lรณpez-Soriano FJ.ย Cachexia and sarcopenia: mechanisms and potential targets for intervention.ย Current Opinion in Pharmacology 2015; 22: 100โ€“106.

Bowen TS, Schuler G, Adams V.ย Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.ย J Cachexia Sarcopenia Muscle 2015; 6: 197โ€“207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!